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S44 Journal of Thoracic Oncology Vol. 11 No. 2Sto be signiﬁcantly overexpressed, suggesting that OIP5-
AS1 may negatively regulate its sense counterpart. In
addition, we ﬁnd that expression of both OIP5 and OIP5-
AS1 are signiﬁcantly associated with 5-year survival.
These ﬁndings suggest that deregulation of OIP5 through
its antisense RNA may represent a novel mechanism
regulating tumor phenotypes in NSCLC.
ART1, an extracellular
ADP-ribosyltransferase, is
over-expressed in non-small cell lung
cancer and facilitates cancer cell
survival by immune-mediated
mechanismsChuang Chen, Christopher Agrusa,
Abu Nasar, Esi Kajno, Nasser K. Altorki,
Timothy E. McGraw, Brendon M. Stiles Weill Cornell
Medicine, New York, NY
Cell surface mono-ADP ribosyltransferases (ARTs)
transfer the ADP-ribose moiety from NADþ to amino
acid residues on target proteins and post-translationally
regulate their function. Most mammalian mono-ARTs,
including ADP-ribosyltransferase 1 (ART1) reside on the
cell surface, however the scope of extracellular mono-
ADP-ribosylation is largely unknown. It has been sug-
gested that epithelial cells in the injured or inﬂamed lung
may overexpress ART1 as a mechanism of cell survival to
protect against cell clearance by inﬂammatory cells. We
hypothesize that ART1 expression is cytoprotective to
lung cancer cells and facilitates metastatic growth.
We found ART1 to be expressed in multiple human
NSCLC cell lines of distinct driver mutation status by RT-
PCR, western blots, and immunoﬂuorescent staining. Using
biobanked human materials, we also found evidence of
ART1 expression in human NSCLC tumors by whole tumor
RT-PCR, immunoﬂuorescence, and immunohistochemistry.
Compared tomatchedadjacent normal lung (n¼40), byRT-
PCR there is over a 2-fold increase (p¼0.01) in median
tumor expression of ART1, suggesting a role in tumori-
genesis or tumor progression. We subsequently stained a
tissue microarray containing 184 cases of predominantly
(74%) stage I NSCLC to determine the prevalence of NSCLC
tumors staining positive for ART1. ART1 staining was
moderate or strong in 83% of adenocarcinomas (n¼145)
and in 45% of squamous cell cancers (n¼39, p<0.001).
We next used murine cell lines derived from inducible
KRASG12D/þ/p53-/- mice and an in vivo model to deter-
mine the effect of ART1 expression onmetastatic outgrowth.
In a tail vein injection model in immunocompetent mice, we
noted a highly signiﬁcant decrease in metastasis in the
ART1-knockdown cell line (sh175) compared to the parentKP1 line. To determine whether the immune protective ef-
fect mediated by ART1 may be T cell dependent, we
implanted ﬂank tumors in immunocompetent (B6) and
lymphocyte-depleted nude mice. Despite slightly faster in
vitro rates of growth, sh175KP1 cells lacking ART1 expres-
sion were largely unable to form tumors when injected into
the ﬂanks of immunocompetent B6 mice. Only 1 of 5
immunocompetent mice injected with sh175KP1 cells
developed a tumor, compared to 5 of 5 mice injected with
KP1 control cells. However, in lymphocyte-depleted nude
mice, there was robust ﬂank tumor growth with both cell
lines. Because the sh175KP1 cells lacking ART1 only had a
disadvantage to growth in mice with lymphocytes, we can
infer that ART1 expression may have a strong immunomo-
dulating effect on that cell population.We also evaluated the
effect of ART1 expression on neutrophil cytotoxicity. At a
neutrophil:tumor cell ratio of 20:1, the knockdown cell line
sh175KP1 lacking ART1 expression is more sensitive to
neutrophil-induced apoptosis in the co-culture assay (87%
vs. 56% Annexin V positive, p¼0.05). Importantly, chemical
inhibition of mono-ADP-ribosylation in the parent KP1 cell
line with two well established inhibitors, novobiocin and
meta-iodobenzylguanidine, facilitated neutrophil-induced
apoptosis, implying that the enzymatic activity of ART1 is
critical to the phenotype.
We provide evidence that ART1 is overexpressed in
NSCLC. ADP-ribosylation may serve as a defense against
immune-mediated cytotoxicity. Cells without ART1 expres-
sion are more sensitive to cytotoxicity induced by immune
cells and these cells have a markedly decreased capacity to
grow in the lungs in an immunocompetentmetastaticmodel.
Because ART1 is an extracellular enzymatic target, it is ex-
pected to be highly druggable and susceptible to therapeutic
intervention. We envision using targeted inhibition of ADP-
ribosylation in ART1-overexpressing tumors to facilitate
immune-mediated destruction of established cancers or of
micrometastatic disease.
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Introduction: Molecular testing is routinely performed in
patients with metastatic non-small cell lung cancer. As the
February 2016 Abstracts S45clinical use of targeted drugs for patients with stage IV
disease accelerates, it is logical to speculate that such drugs
could also be used in patients with early stage (I-III) dis-
ease. For example, the Adjuvant Lung Cancer Enrichment
Marker Identiﬁcation and Sequencing Trials (ALCHEMIST)
will begin to offer genetic screening of surgically resected
lung adenocarcinomas as a platform to test molecularly
targeted adjuvant therapy. Currently, the value of routine
molecular testing of resected NSCLC is not known. Addi-
tionally, little has been published on the rates of mutations
as determined using routine next-generation DNA
sequencing (NGS) in patients with early stage disease. We
therefore sought to review our early experience utilizing
reﬂex testing of a 50-gene cancer panel with interpretation
in resected early stage lung cancer specimens.
Methods: Since January 2015, specimens from all pa-
tients undergoing surgical resection for lung adenocar-
cinoma were submitted for routine mutational proﬁling
by NGS and ALK rearrangement testing by FISH. The
targeted gene panel is designed to detect mutations/
variants in 50 key cancer-related genes. This test was
validated for mutations/Single Nucleotide Variants
(SNV) in the BRAF, EGFR, HRAS, IDH1, JAK2, KIT, KRAS,
MET, NRAS, and PIK3CA genes. The limit of detection is
precise and reproducible at approximately 5% with
approximately 400X coverage and 3% with 1000X
coverage. The data obtained was analyzed with the
Torrent Suite Software v 4.4. DNA sequences used as
references for this panel of genes can be found at
(http://www.ncbi.nlm.nih.gov/refseq/rsg/). The muta-
tion nomenclature is based on the recommendations
from the Human Genome Variation Society (http://www.
hgvs.org/mutnomen/). Mutations were classiﬁed as Tier
1 (clinical utility demonstrated in NSCLC), Tier 2 (utility/
actionability or therapeutic implications have been sug-
gested in different tumor types or preclinical models)
and Tier 3 (variants of uncertain signiﬁcance). Clinical
and pathologic characteristics of patients were entered
into a prospectively maintained database and compared
among patients with and without mutations.
Results: From January-October 2015, we performed 205
resections for NSCLC of which 148 were adenocarci-
nomas suitable for analysis. One hundred twenty pa-
tients (81%) had at least one mutation, while 39 patients
(26%) had >1 mutation or rearrangement. Among total
mutations, we detected 42 Tier 1 variants, 68 Tier 2
variants, and 54 Tier 3 variants (Table). Among Tier 1
variants, EGFR mutations were the most common (n¼41,
28% of patients from entire cohort). Patients with EGFR
mutations were more likely to have been never smokers
(54% vs. 16%, p<0.01) and more likely to be Asian
(49% vs. 4%, p<0.01), but had similar gender distribu-
tion (female 71% vs. 64%, p¼0.411). Among EGFRþpatients, 39% were stage IB-III and eligible for adjuvant
therapy. Among other Tier 1 variants, we only detected 1
(1%) ALK rearrangement. Among Tier 2 variants, KRAS
mutations were the most common (n¼51, 34% of entire
cohort), while BRAF and PIK3CA mutations were also
present in more than 2% of total patients. Compared to
other patients, KRASþ patients were more likely to be
current or former smokers (94% vs. 63%, p< 0.01).
Among patients with KRAS mutations, 29% (n¼15) had
stage IB-III disease. For other patients with Tier 2 vari-
ants, 8 out of 17 patients (12% of Tier 2 patients, 5% of
entire cohort) had stage IB-III disease. Among all pa-
tients with pathologic stage IB-III lung adenocarcinoma,
85% had mutations discovered.
Conclusions: Routine molecular testing of tumors from
patients with resected lung adenocarcinoma is associ-
ated with high rates of mutation discovery. In our series,
69% of patients had Tier 1 or 2 variants which are
presumably actionable. This included 36% of total pa-
tients who were stage IB-III with at least one mutation.
These patients would be eligible for adjuvant therapy
and could be considered for trials of molecularly tar-
geted therapeutics.
Mutation N (%) Number with stage IB-III
None 28 (19%) 8 (29%)
Tier 1 Total 42 17 (40%)
EGFR 41 (28%) 16 (39%)
ALK (re) 1 (1%) 1 (100%)
Tier 2 Total 68 23 (34%)
KRAS 51 (34%) 15 (29%)
BRAF 7 (5%) 3 (43%)
PIK3CA 4 (3%) 3 (75%)
MET 2 (1%) 0 (0%)
ERBB2 1 (1%) 1 (100%)
NRAS 1 (1%) 0 (0%)
IDH1 1 (1%) 1 (100%)
JAK2 1 (1%) 0 (0%)
Tier 3 Total 54 28 (52%)
P53 34 (23%) 16 (47%)
APC 5 (3%) 3 (60%)
ATM 4 (3%) 2 (50%)
JAK3 3 (2%) 2 (67%)
CDKN2A 2 (1%) 2 (100%)
MLH1 2 (1%) 2 (100%)
SMAD4 1 (1%) 1 (100%)
PTEN 1 (1%) 0 (0%)
STK11 1 (1%) 0 (0%)
GNAS 1 (1%) 0 (0%)
